Last reviewed · How we verify
NCT05958199
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Phase 1 trial testing NPX267 in Metastatic Malignant Neoplasm in 131 participants. Suspended.
20 September 2025
Quick facts
| Lead sponsor | NextPoint Therapeutics, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 131 |
| Start date | 21 July 2023 |
| Primary completion | 20 September 2025 |
| Estimated completion | 20 September 2025 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- NPX267 — full drug profile →
Conditions studied
- Metastatic Malignant Neoplasm — all drugs for Metastatic Malignant Neoplasm →
Sponsor
NextPoint Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Metastatic Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are: * what is an appropriate dose to be given to patients? * are the side effects of treatment manageable? Participants will be evaluated for participation in the study. Patients who are treated will receive an intravenous infusion of NPX267 every three weeks if their disease has not progressed. Patients will be closely monitored by the treating physician.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review.
Zhou H, Zeng Y, Hida T, Hsu R, et al · · 2024 · cited 7× · PMID 39830739 · DOI 10.21037/tlcr-24-964 -
Research on Targeted Therapy for Malignant Tumors of the Biliary Tract.
Yang Y, Zhong H, Zhang J, Wang P. · · 2026 · PMID 42146765 · DOI 10.2147/ott.s593457
Verify or expand the search:
- PubMed search for NCT05958199
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Malignant Neoplasm
Currently open trials in the same condition.
- NCT04150939 — Cryoablation for the Treatment of Metastatic Cancer · NA · active not recruiting
- NCT04068649 — Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer · Phase 2 · recruiting
- NCT03743649 — Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Under · Phase 2, PHASE3 · active not recruiting
- NCT04053517 — Financial Distress in Advanced Cancer Patients · active not recruiting
- NCT03671226 — Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05958199 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NextPoint Therapeutics, Inc.
- Last refreshed: 27 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05958199.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing